ID   Ma-Mel-100a
AC   CVCL_A124
SY   Ma-Mel-100; MaMel100
DR   cancercelllines; CVCL_A124
DR   Cosmic; 1846569
DR   Cosmic; 2686335
DR   Cosmic; 2757116
DR   GEO; GSM1467849
DR   Progenetix; CVCL_A124
DR   Wikidata; Q54903735
RX   PubMed=17311103;
RX   PubMed=23348503;
RX   PubMed=25294904;
RX   PubMed=26909863;
CC   Sequence variation: Gene deletion; HGNC; HGNC:914; B2M; Zygosity=Heterozygous (PubMed=25294904).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Gene fusion; HGNC; HGNC:7413; MTAP + HGNC; HGNC:34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A1DY ! Ma-Mel-100b
SX   Male
AG   76Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 21
//
RX   PubMed=17311103; DOI=10.1371/journal.pone.0000236; PMCID=PMC1794595;
RA   Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A.,
RA   Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R.,
RA   Schadendorf D.;
RT   "B-RAF and N-RAS mutations are preserved during short time in vitro
RT   propagation and differentially impact prognosis.";
RL   PLoS ONE 2:e236.1-e236.13(2007).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=25294904; DOI=10.1158/1078-0432.CCR-14-0567; PMCID=PMC8728890;
RA   Sucker A., Zhao F., Real B., Heeke C., Bielefeld N., Massen S.,
RA   Horn S., Moll I., Maltaner R., Horn P.A., Schilling B., Sabbatino F.,
RA   Lennerz V., Kloor M., Ferrone S., Schadendorf D., Falk C.S.,
RA   Griewank K.G., Paschen A.;
RT   "Genetic evolution of T-cell resistance in the course of melanoma
RT   progression.";
RL   Clin. Cancer Res. 20:6593-6604(2014).
//
RX   PubMed=26909863; DOI=10.18632/oncotarget.7503; PMCID=PMC4941330;
RA   Xie H.-P., Rachakonda P.S., Heidenreich B., Nagore E., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Mapping of deletion breakpoints at the CDKN2A locus in melanoma:
RT   detection of MTAP-ANRIL fusion transcripts.";
RL   Oncotarget 7:16490-16504(2016).
//